

TABLE OF CONTENTS

Module 1

PRINCIPLES OF GENETIC MEDICINE

Key Words	1
Abstract	1
Outline	2
Learning Objectives	3
Abbreviations in this Chapter	3
Central Assumptions of Genetics and Genetic Medicine	4
What is Genetics?	4
Premendelian Concepts	4
The Location of the Genetic Material	6
What is a Gene?	7
What do Genes do?	16
The Basic Vocabulary of Genetics and the Basic Principles of	
Inheritance	17
Some Key Definitions	17
Mendelian Genetics and Single-gene Inheritance	17
Mendel and Darwin	19
Autosomal Dominant Inheritance	19
Autosomal Recessive Inheritance	22
X-linked Disorders	23
Exceptions to Mendelian Inheritance	24
X-inactivation and the Lyon Hypothesis	24
Mitochondria and Maternal Inheritance	26
Genetic Anticipation	27
Genetic Imprinting	29
Uniparental Disomy	29
How Do Disorders Caused Primarily by Single-gene Mutations	
Differ from Multifactorial or Complex Disorders?	30
Terms and Definitions	30
Uncertainties Regarding Risks	31
Single-gene Disorders as Complex Diseases—Hemochromatosis	32
Age at Onset	34
Environmental Issues	34
Population Genetics	34
Understanding and Learning How to Access New Genetic	
Technology	35

Advances in Technology	35
The Southern Blot	35
Vectors	39
Genetic Libraries	39
Reverse Transcriptase	39
Polymerase Chain Reaction	40
Stem Cells	40
Perspectives on Gene Therapy	41
Genetics in Medicine Today—The New Genetics	43
Genetic Counseling	43
References	44
Web Sites	44
Genetics Societies	44
Additional Useful Sites	44
Self-Assessment Questions	47

APPLIED MOLECULAR AND CELLULAR BIOLOGY

Key Words	53
Abstract	53
Outline	53
Learning Objectives	55
Abbreviations in this Chapter	55
Introduction	56
Structure and Function of Eukaryotic Cells	57
The Nucleus	57
The Cytoplasm	60
Protein Processing Organelles	60
Ribosomes	60
Endoplasmic Reticulum	61
Golgi Complex	62
Lysosomes	64
Metabolic Organelles	64
Mitochondria	64
Peroxisomes	66
Gene Processing and Regulation	66
DNA Replication	66
Proteins Involved in DNA Replication	67
Topoisomerases	67
DNA Helicases	67
DNA Polymerases	67
Origins and Initiation of Replication	68
The DNA Replication Fork	69
Transcription	69
RNA Polymerases	70
Basal Promoter	71

Upstream Promoter Elements	71
Stages of Transcription	71
Elongation	73
Termination	73
RNA Processing	74
5'-Capping	75
3'-Polyadenylation	75
Splicing	75
Transcriptional Gene Regulation	76
Transcriptional Activators and Repressors	76
Enhancers, Silencers, and Insulators	78
Steroid Hormone Receptors and Transcription Regulation	79
DNA Methylation	80
Histone Acetylation	80
Translation (Protein Synthesis)	81
Ribosomal RNA	81
Transfer RNA	82
Initiation of Translation (Formation of the Initiation Complex) ..	82
Elongation of Polypeptide Chain (New Protein)	83
Termination of Protein Synthesis	84
Regulation of Translation	85
Stabilization of mRNA	86
Post-translational Modification	87
Cell Signaling	88
Cell Signaling Molecules	89
Plasma Membrane Diffusion	89
Ion Channels	90
G Protein-coupled and Enzyme-linked Receptors	90
G Protein-coupled Receptors	90
G Protein-coupled Receptors and G Protein Structure	91
G Protein-coupled Receptor Signaling	93
G Protein-coupled Receptor Diversity and Specificity	94
Implications for Drug Therapy	95
Enzyme-linked Receptors	97
Receptor Tyrosine Kinases and RTK Structure	97
Ras, Raf and RTK Signaling	97
Implications for Drug Therapy	99
Janus Family Tyrosine Kinase/Signal Transducer and Activator of Transcription Signaling Pathway	100
Summary	103
References	104
Self-Assessment Questions	114

ANALYSIS OF THE HUMAN GENOME AND PROTEOME

Key Words	117
-----------------	-----

Abstract	117
Outline	117
Learning Objectives	118
Abbreviations in this Chapter	118
Historical Perspectives	119
Technologies Driving DNA-based Discoveries	121
Analysis of the Human Genome by PCR Amplification	121
Direct DNA Sequencing	124
Expressed Sequence Tags	127
The Gene-to-Function-to-Potential Drug Paradigm	127
Deriving Drug Targets by EST Analysis: Discovery of Cathepsin K	128
Identification of DNA Sequence Variations, SNPs	129
Identification of SNPs by Sequence Analysis, Detection of DNA Polymorphisms	130
Detection of DNA Polymorphisms by Single-strand Conformational Polymorphism Analysis	130
Detection of DNA Sequence Polymorphisms by RFLP	131
Detection of DNA Sequence Polymorphisms by Microsatellite Analysis	133
Gene Expression Profiling	137
Expression Profiling by Microarray Analysis	137
Microarray Analysis of Nonhuman Genomes: Host-Microbe Interactions	141
Methods for Analyzing the Human Proteome	142
Methods for Transferring Specific Genetic Sequences—Gene Therapy Techniques and Applications	145
Conclusions and Future Directions	149
Summary of Referenced Web Sites	149
References	150
Self-Assessment Questions	153

BIOINFORMATICS

Key Words	155
Abstract	155
Outline	155
Learning Objectives	156
Abbreviations in this Chapter	156
Introduction	157
What is Bioinformatics?	157
Historical Background	158
Theoretical Foundations	159
Database Resources	161
Introduction to NCBI	161
Types of Databases	161

The Genbank Entry	161
SWISS-PROT and RefSeq	163
Genome Databases	166
Single Nucleotide Polymorphism Databases	166
Sequence Alignment	166
Sequence Homology	166
Dot-matrix Comparisons	167
Pairwise Sequence Alignment	168
Multiple Sequence Alignment	171
Homology Searches	172
Sequence Comparisons	173
Amino Acid Sequence Comparisons	173
Nucleotide Sequence Comparisons	175
Phylogenetic Reconstruction	178
General Considerations	178
Maximum Parsimony	180
Minimum Evolution and Other Distance Methods	181
Maximum Likelihood	183
Structure Prediction	184
Gene Expression Data	184
Microarray Data	184
Clustering Methods	186
Prospects for the Future	188
Web Sites of Interest	188
References	188
Self-Assessment Questions	191

APPLICATIONS OF GENOMICS IN HUMAN HEALTH AND COMPLEX DISEASE

Key Words	193
Abstract	193
Outline	194
Learning Objectives	194
Abbreviations in this Chapter	195
Introduction	195
Genome Scanning Techniques	198
Genotyping	198
Messenger Ribonucleic Acid Expression Analysis (Transcriptome)	199
Protein Analysis (Proteome)	200
Metabolite Analysis (Metabolome)	201
Genetic Variability	201
Single Nucleotide Polymorphisms	203
Deoxyribonucleic Acid Microsatellite Variability	205
Microsatellite Analysis of Altered Immune Function	205

Microsatellites and Chromosomal Instability in Cancer	206
Epigenetic Effects	207
Linkage Disequilibrium and Haplotypes	208
Asthma Haplotype Study	210
Coronary Artery Disease and Genetic Predisposition	211
Linking Genotype to Phenotype	213
Monogenic Mendelian Disorders and Polygenic Diseases:	
Family Studies and Positional Cloning	213
Case-control Studies, Population Genetics	215
Genome-wide Association Studies	216
Summary	217
References	218
Self-Assessment Questions	221

ETHICAL, LEGAL, AND SOCIAL ISSUES IN PHARMACOGENOMICS

Key Words	225
Abstract	225
Outline	226
Learning Objectives	227
Abbreviations in this Chapter	227
Ethical, Legal, and Social Issues in Pharmacogenomics	227
Historical Factors Coloring the Uses of Genetic Technology	227
Pharmacogenomics and the Principle of Nonmaleficence	231
Pharmacogenomics and the Principle of Beneficence	232
Pharmacogenomics and the Principle of Autonomy	232
Issues in the Research Context	235
Clinical Ethical Issues in Medical Genetics	236
Informed Consent	236
Confidentiality	237
Nonmedical Uses of Genetic Information and Genetic	
Discrimination	238
Insurance and Genetic Probabilistic Risk Profiles	238
Employment	241
References	245
Self-Assessment Questions	248

Module 2

PHARMACOGENETICS: A HISTORICAL PERSPECTIVE

Key Words	251
Abstract	251
Outline	251

Learning Objectives	253
Abbreviations in this Chapter	253
Early History of Pharmacogenetics	253
Two Independent Old Sciences Found Each Other	253
Genetics	253
Pharmacology	254
The Start of Pharmacogenetics	254
The Rise of Classical Pharmacogenetics	257
The Impact of Molecular Genetics on Pharmacogenetics	259
General Aspects of Molecular Pharmacogenetics	259
Separate Areas of Molecular Pharmacogenetics	260
Patient Classification	260
Drug Metabolism	261
Drug Receptors	261
Interethnic Pharmacogenetics	262
Multifactorial Pharmacogenetics	263
New Problems Arising	265
Variable Gene Expression	265
Drugs Affect Genes	265
Epigenetics	266
Summary	266
References	266
Self-Assessment Questions	271

PHARMACOGENETICS OF OXIDATIVE DRUG METABOLISM AND ITS CLINICAL APPLICATIONS

Key Words	273
Abstract	273
Outline	273
Learning Objectives	274
Abbreviations in this Chapter	274
Oxidative Drug Metabolism	275
Cytochromes P450	275
Genetic Variation and Phenotype Characterization	278
Probe Drugs and Measures of Enzyme Activity	279
Genetic Variation in Oxidative Drug Metabolism	281
Overview	281
Pharmacogenetics of Specific Drug-metabolizing Enzymes	281
The CYP1 Gene Family	281
Cytochrome P450 1A1 and CYP1B1	282
Cytochrome P450 1A2	282
In Vivo Activity	282
Clinical Consequences of Genetic Variation	282
CYP2 Gene Family	284
Cytochrome P450 2A6	284

In Vivo Activity	285
Clinical Consequences of Genetic Variation	285
Cytochrome P450 2B6	285
In Vivo Activity	286
Clinical Consequences of Genetic Variation	286
CYP2C Gene Subfamily	286
Cytochrome P450 2C8	286
In Vivo Activity	287
Clinical Consequences of Genetic Variation	287
Cytochrome P450 2C9	287
In Vivo Activity	287
Clinical Consequences of Genetic Variation	287
Cytochrome P450 2C19	289
In Vivo Activity	289
Clinical Consequences of Genetic Variation	290
Cytochrome P450 2DC	290
In Vivo Activity	291
Clinical Consequences of Genetic Variation	291
Cytochrome P450 2E1	292
In Vivo Activity	292
Clinical Consequences of Genetic Variation	292
CYP3 Gene Family	292
In Vivo Activity	293
Clinical Consequences of Genetic Variation	294
Oxidative Drug Metabolism—Other Enzymes	295
Flavin-containing Monooxygenase Gene Family	295
In Vivo Activity	295
Clinical Consequences of Genetic Variation	296
Approaches for Clinical Application of Oxidative Drug	
Metabolism Pharmacogenetics	296
Integration into Therapy Selection Process	296
Pharmacogenetics-oriented Therapeutic Drug Monitoring	297
References	298
Self-Assessment Questions	305

DRUG TRANSPORTER PHARMACOGENETICS

Key Words	309
Abstract	309
Outline	309
Learning Objectives	310
Abbreviations in this Chapter	310
Human Drug Transporters—Localization and Function	311
Efflux Transporters	311
MDR1 (ABCB1)	311
Multidrug Resistance-associated Proteins	312

MRP1 (ABCC1)	312
MRP2 (ABCC2)	312
MRP3 (ABCC3)	313
MRP4 (ABCC4)	313
MRP5 (ABCC5)	313
MRP6 (ABCC6)	313
MRP7 (ABCC7)	313
Mitoxantrone Resistance Protein/Breast Cancer Resistance Protein (ABCG2)	314
Physiological Function of Multidrug Resistance Efflux Transporters	314
Uptake Transporters	314
Organic Cation Transporters	314
OCT1 (SLC22A1)	315
OCT2 (SLC22A2)	315
OCT3 (SLC22A3)	315
OCTN1 (SLC22A4)	315
OCTN2 (SLC22A5)	316
Physiological Function of Organic Cation Transporters	316
Organic Anion Transporters	316
OAT1 (SLC22A6)	317
OAT3 (SLC22A8)	317
OAT4 (SLC22A11)	317
OATP1 (OATP-A, SLC21A3)	317
OATP-B (SLC21A9)	318
OATP2 (OATP-C, LST1, SLC21A6)	318
OATP-D (SLC21A11), OATP-E (SLC21A12) and OATP-F (SLC21A14)	318
OATP8 (SLC21A8)	318
Physiological Function of Organic Anion Transporters	318
Nucleoside Transporters	319
ENT1 (SLC29A1)	319
ENT2 (SLC29A2)	319
ENT3	319
CNT1 (SLC28A1)	320
CNT2 (SLC28A2)	320
CNT3 (SLC28A3)	320
Physiological Function of Nucleoside Transporters	320
Genetic Variability in Drug Transporters	321
Efflux Transporters	321
MDR1	321
Multidrug Resistance-associated Protein	322
MRP1	322
MRP2	323
MRP6	323

Mitoxantrone-resistance Protein	323
Uptake Transporters	323
Organic Cation Transporters	323
hOCT1	323
hOCT2	324
Organic Anion Transporters	324
OATP-A	324
OATP-B	324
OATP-C	324
OATP8	324
Clinical Consequences of Genetic Variability in Drug Transporters	325
Efflux Transporters	325
MDR1	325
MRP2	327
MRP6	327
Uptake Transporters	327
OCTN2	327
Perspectives	327
References	328
Self-Assessment Questions	334

DRUG TARGET PHARMACOGENETICS

Key Words	337
Abstract	337
Outline	338
Learning Objectives	338
Abbreviations in this Chapter	339
Introduction	339
Drug Target Versus Drug Metabolism Pharmacogenetics:	
Comparisons and Contrasts	340
Functional Consequences of Genetic Polymorphisms	340
Phenotypes Resulting from Genetic Polymorphisms	341
Drug Target Pharmacogenetics	342
Polymorphisms of Direct Drug Targets and Association with Drug Response	343
Polymorphisms of Signal Transduction/Downstream Proteins and Associations with Drug Response	349
Polymorphisms of Disease Pathogenesis Proteins and Associations with Drug Response	349
Drug Targets in Infectious Disease and Cancer	352
Limitations of Current Literature	353
Moving Drug Target Pharmacogenetics from Proof of Concept to Clinical Practice	354
Using Genotype Information to Predict Response	354

Assessment of Clinical Value of Genetic Tests	354
Predictability of Response Based on Genotype—Examples from the Literature	355
Moving Drug Target Pharmacogenetics/Genomics from Proof of Concept to Clinical Practice	357
Genomic Approaches to Describing Drug Response Variability . . .	359
Candidate Gene Approach	359
Genome Scanning Approach	360
Clinical Potential for Drug Target Pharmacogenetics	361
References	363
Self-Assessment Questions	373

PHARMACOGENOMICS IN DRUG DISCOVERY AND DRUG DEVELOPMENT

Key Words	377
Abstract	377
Outline	378
Learning Objectives	378
Abbreviations in this Chapter	378
Introduction	379
Pharmacogenomics in Drug Discovery	380
New Target Discovery	380
Toxicogenomics	381
Pharmacogenomics in Drug Development	383
Postmarketing Surveillance	388
Regulatory Concerns	390
Ethical Concerns	391
Conclusions	392
References	392
Self-Assessment Questions	395

SOCIETAL AND ETHICAL ISSUES IN PHARMACOGENOMICS

Key Words	399
Abstract	399
Outline	400
Learning Objectives	401
Abbreviations in this Chapter	401
Societal and Ethical Issues in Pharmacogenomics	401
Current Controversies over Race in Science	401
A Brief History of Race	405
Race and Justice in Pharmacogenomics	413
Pharmacogenetics and Access to Health Care	417
Pharmacogenetics in Research and Development	423
Conclusions	434
References	435

Self-Assessment Questions	440
---------------------------------	-----

Module 3

ONCOLOGY AND HEMATOLOGY

Key Words	443
Abstract	443
Outline	443
Learning Objectives	444
Abbreviations in this Chapter	444
Introduction	445
Carcinogenesis	446
Overview	446
Genetic Susceptibility to Cancer	446
Xenobiotic Drug Metabolizing Enzymes	447
Deoxyribonucleic Acid Repair Enzymes	448
Treatment-related or Secondary Malignancies	449
Genetic Mutations in the Diagnosis of Disease	450
American Society of Clinical Oncology Guidelines	451
Criteria for a Genetic Test	451
Autosomal Dominant Cancer Syndromes	452
Hereditary Colon Cancer	452
Hereditary Nonpolyposis Colon Cancer	453
Hereditary Medullary Carcinoma	454
Breast Cancer and Ovarian Cancer	455
Molecular Characterization of Hematological Malignancies	457
Chronic Myelogenous Leukemia	457
Chronic Lymphocytic Leukemia	458
Myelodysplasias	458
Acute Myeloid Leukemia	459
Acute Lymphoblastic Leukemia	459
Use of Pharmacogenetics and Pharmacogenomics in Oncology ...	460
6-Mercaptopurine	460
5-Fluorouracil and Capecitabine	461
Dihydropyrimidine Dehydrogenase	461
Thymidylate Synthase	462
Irinotecan	463
UDP-Glucuronosyltransferase	463
Topoisomerase I	463
Platinum Agents	463
Deoxyribonucleic Acid Repair Polymorphisms	463
GSTP1-1 Polymorphism	464
Purines and Pyrimidine Analogs	464

Cytochrome P450 Polymorphisms and Drug Response	465
Cytochrome P450 2D6	465
Drug Efflux Pumps	465
P-glycoprotein	465
Drug Development	466
Acute Myelogenous Leukemia-M3 and the Development of Tretinoin	466
Chronic Myelogenous Leukemia and the Development of Imatinib	466
Monoclonal Antibodies	467
Conclusion	467
References	467
Self-Assessment Questions	470

INFECTIOUS DISEASES

Key Words	473
Abstract	473
Outline	473
Learning Objectives	474
Abbreviations in this Chapter	474
Introduction	475
Genetic Predisposition to Infection in the Host	475
Interindividual Variation and Genetic Association with Susceptibility to Infectious Diseases	475
Pathogen Genomics	477
Microbial Physiology	477
Virulence	478
Anti-infective Resistance	479
Host-Pathogen Interactions	479
Innate Immune Response	480
Pathogen Response to Host Contact	482
Genomics in Drug Discovery and Development	482
Novel Targets	482
Targeted Patient Populations	483
Pharmacogenomics in Infectious Diseases	483
Drug Metabolism	483
Drug Targets	484
Vaccines and Genomics	487
Vaccine Response	487
Reverse Vaccinology	487
Conclusion	487
References	488
Self-Assessment Questions	491

CARDIOVASCULAR DISEASES

Key Words	495
Abstract	495
Outline	495
Learning Objectives	496
Abbreviations in this Chapter	497
Introduction	497
Limitation to the Current Pharmacological Approach to Cardiovascular Disease Management	497
Sites of Polymorphisms that Influence the Interpatient Variability in Cardiovascular Drug Response	498
Influence of Environmental-genetic Interactions on Cardiovascular Drug Response	498
Pharmacogenomics of Drugs for Treating Hypertension and Heart Failure	499
Diuretics	500
Renin-angiotensin System Antagonists	502
β -Blockers	504
Digoxin	507
Explanations for Inconsistent Data	508
Application of these Data to Clinical Practice	510
Prediction of Other Responses that Might Have a Genetic Basis	512
Pharmacogenomics of Anticoagulant and Antiplatelet Agents	512
Warfarin	513
Heparin	515
Glycoprotein IIb/IIIa Inhibitors and Aspirin	515
Application of these Data to Clinical Practice	517
Predicting Responses to Other Antiplatelet Agents and Newer Antithrombotic Agents that Might Have a Genetic Basis	517
Pharmacogenomics of Lipid-lowering Drugs	518
Statins	518
Fibrates	521
Application of these Data to Clinical Practice	521
Prediction of Other Responses to Lipid-lowering Drugs that Might Have a Genetic Basis	522
Pharmacogenomics of Antiarrhythmic Agents	522
Procainamide	522
Propafenone	523
Drugs Causing QT Interval Prolongation	523
Applying Data to Clinical Practice	524
Prediction of Other Responses to Antiarrhythmic Drugs that Might Have a Genetic Basis	525
Conclusion	525
References	526
Self-Assessment Questions	530

CENTRAL NERVOUS SYSTEM/ PSYCHIATRY

Key Words	533
Abstract	533
Outline	534
Learning Objectives	534
Abbreviations in this Chapter	535
Introduction	535
Central Nervous System Disorders	536
Multiple Sclerosis	536
Migraine	536
Alzheimer's Disease	537
Parkinson's Disease	540
Epilepsy	541
Psychiatry	542
Depression	542
Schizophrenia	544
Serotonin and Dopamine Receptors and Antipsychotic Response	544
Cytochrome P450 Isoenzymes and Antipsychotic Pharmacokinetics	545
Pharmacogenetics and Weight Gain from Antipsychotics	547
Pharmacogenetics and Tardive Dyskinesia Development	549
Pain and Opioid Abuse	551
Opioid Receptors	551
Dopamine and Serotonin Receptors	552
Cytochrome P450	552
Drug Efflux from CNS and across the Blood-brain Barrier	553
P-glycoprotein	553
Microarray Techniques and CNS	553
Conclusion	555
References	555
Self-Assessment Questions	568

RESPIRATORY DISEASES

Key Words	571
Abstract	571
Outline	572
Learning Objectives	573
Abbreviations in this Chapter	573
Introduction	575
Asthma	576
Epidemiology	576
Asthma Genetics	577
Current Guidelines for Asthma Treatment	577
Glucocorticoids	578

Leukotriene Receptor Antagonists	578
Interpatient Variability in Response to ICSs and LTRAs	581
Pharmacogenetics of ICSs	582
Pharmacogenetics of Inhibitors and Antagonists of the Cys-Leukotriene Pathway	582
Other Leukotriene Pathway Polymorphisms	584
β_2 Adrenergic Receptor Agonists	584
Long-acting Beta Agonist Use in Asthma	586
Pharmacogenetics of β_2 Agonists in Asthma	587
Moving Asthma Pharmacogenetics to the Clinic	590
Chronic Obstructive Pulmonary Disease	591
Epidemiology	591
Asthma and COPD	592
Environmental Influence and Genetic Predisposition	592
Racial/Ethnic Differences in COPD Prevalence	594
α -1-Antitrypsin Deficiency	594
Other Genetic Factors in COPD	596
Guidelines for COPD Treatment	596
Smoking Cessation	598
Drug Treatment of COPD	599
Bronchodilators	600
Glucocorticoids	600
Chronic Obstructive Pulmonary Disease Pharmacogenetics	601
References	601
Self-Assessment Questions	613

TRANSPLANTATION

Keywords	617
Abstract	617
Outline	618
Learning Objectives	619
Abbreviations in this Chapter	619
Pharmacogenomics in Transplantation	619
Introduction	619
Adverse Effects are a Problem in Transplantation	620
Drug and Dose Individualization is Needed in Organ Transplantation	620
Multiple Types of Drugs are used in Organ Transplant Patients	621
Drug Disposition Markers	621
P-glycoprotein	621
P-glycoprotein and Drug Absorption	621
Cyclosporine/Tacrolimus Absorption and MDR1 Genotype	623
P-glycoprotein and Renal Function	624
P-glycoprotein and Blood-brain Barrier	626

P-glycoprotein and Steroid Effect	626
P-glycoprotein and Ethnic Differences in Acute Rejection/Graft Survival	627
P-glycoprotein and Rejection/Graft Survival	628
Cytochrome P450 3A4/5	628
Thiopurine Methyltransferase	632
Drug Targets	633
Cytokines	633
Chemokines	635
Adhesion Molecules	636
Growth Factors	637
Applications to Transplant Patients in the Future	637
References	638
Self-Assessment Questions	645